Astria Therapeutics/$ATXS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Astria Therapeutics
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.
Ticker
$ATXS
Sector
Primary listing
Employees
78
Headquarters
Website
ATXS Metrics
BasicAdvanced
$469M
-
-$2.02
0.48
-
Price and volume
Market cap
$469M
Beta
0.48
52-week high
$11.85
52-week low
$3.56
Average daily volume
439K
Financial strength
Current ratio
14.885
Quick ratio
14.364
Long term debt to equity
1.292
Total debt to equity
1.829
Profitability
Management effectiveness
Return on assets (TTM)
-25.28%
Return on equity (TTM)
-38.49%
Valuation
Price to book
2.84
Price to tangible book (TTM)
2.84
Price to free cash flow (TTM)
-4.152
Free cash flow yield (TTM)
-24.08%
Free cash flow per share (TTM)
-2.001
Growth
Earnings per share change (TTM)
-6.27%
3-year earnings per share growth (CAGR)
-15.80%
What the Analysts think about ATXS
Analyst ratings (Buy, Hold, Sell) for Astria Therapeutics stock.
Bulls say / Bears say
Net loss increased to $33.1 million in Q2 2025 from $24.2 million a year earlier, signaling mounting operating losses and financial pressure. (Reuters)
Research and development expenses rose to $25.9 million in Q2 2025 from $20.7 million in Q2 2024, highlighting a higher cash burn as clinical programs progress. (Reuters)
Net cash used in operating activities jumped to $34.0 million in Q1 2025 compared to $19.1 million in Q1 2024, showing increased cash burn as development speeds up. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 7 Oct 2025.
ATXS Financial Performance
Revenues and expenses
ATXS Earnings Performance
Company profitability
ATXS News
AllArticlesVideos
Astria Therapeutics to Present at Upcoming 2025 HAEi Regional Conference EMEA
Business Wire1 week ago
Astria Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire1 week ago
Astria Therapeutics Announces Positive Initial Results from the Phase 1a Healthy Subject Trial of STAR-0310 at the European Academy of Dermatology and Venereology
Business Wire4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Astria Therapeutics stock?
Astria Therapeutics (ATXS) has a market cap of $469M as of October 12, 2025.
What is the P/E ratio for Astria Therapeutics stock?
The price to earnings (P/E) ratio for Astria Therapeutics (ATXS) stock is 0 as of October 12, 2025.
Does Astria Therapeutics stock pay dividends?
No, Astria Therapeutics (ATXS) stock does not pay dividends to its shareholders as of October 12, 2025.
When is the next Astria Therapeutics dividend payment date?
Astria Therapeutics (ATXS) stock does not pay dividends to its shareholders.
What is the beta indicator for Astria Therapeutics?
Astria Therapeutics (ATXS) has a beta rating of 0.48. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.